Related Experiment Video
Updated: Aug 17, 2026
In Vivo Dynamics of Retinal Microglial Activation During Neurodegeneration: Confocal Ophthalmoscopic Imaging and Cell Morphometry in Mouse Glaucoma
Published on: May 11, 2015
Microglial activation induced by neurodegeneration: a proteomic analysis
Yong Zhou1, Yan Wang, Monika Kovacs
1Department of Pathology, University of Washington School of Medicine, Seattle, Washington 98104, USA.
Abstract:
Neuroinflammation mediated by microglial activation appears to play an essential role in the pathogenesis of Parkinson disease; however, the mechanisms by which microglia are activated are not fully understood. Thus, we first evaluated the effects of two parkinsonian toxicants, manganese ethylene bisdithiocarbamate (Mn-EBDC) and 1-methyl-4-phenylpyridine (MPP+), on microglial activation as well as associated dopaminergic (DAergic) neurotoxicity in primary cell culture systems. The results demonstrated that, when rat primary mesencephalic neuron-enriched or neuron-microglia mixed cultures were treated with Mn-EBDC at 2-8 microm or MPP+ at 0.25-5 microm, respectively, for 7 days, both toxicants were capable of inducing DAergic neurodegeneration as well as activating microglia via a mechanism secondary to DAergic neurodegeneration. Furthermore activated microglia subsequently enhanced DAergic neurotoxicity induced by Mn-EBDC or MPP+. Detailed scrutiny of neuron-microglia interactions identified a fraction of the conditioned media derived from a DAergic cell line treated with Mn-EBDC or MPP+ that potently activated microglia. To further define potential mediators leading to microglial activation secondary to neurodegeneration, we utilized a quantitative proteomic technique termed SILAC (for stable isotope labeling by amino acids in cell culture) to compare the protein profiles of MPP+-treated cellular fraction that mediated microglial activation as compared with controls. The search revealed numerous novel proteins that are potentially important in neurodegeneration-mediated microglial activation, a process believed to be critical in Parkinson disease progression.
Insights
Parkinson disease involves neuroinflammation from microglial activation. This study shows toxicants like Mn-EBDC and MPP+ cause neurodegeneration, which then activates microglia, worsening the damage.
Area of Science:
- Neuroscience
- Neuroimmunology
- Toxicology
Background:
- Microglial activation and neuroinflammation are implicated in Parkinson disease pathogenesis.
- The precise mechanisms driving microglial activation in this context remain unclear.
Purpose of the Study:
- To investigate the effects of manganese ethylene bisdithiocarbamate (Mn-EBDC) and 1-methyl-4-phenylpyridine (MPP+) on microglial activation and dopaminergic neurotoxicity.
- To elucidate the role of neuron-microglia interactions in Parkinson disease progression.
Main Methods:
- Primary cell cultures (neuron-enriched and mixed neuron-microglia) were treated with Mn-EBDC or MPP+.
- Quantitative proteomic analysis using stable isotope labeling by amino acids in cell culture (SILAC) was employed.
- Neuron-microglia interactions and conditioned media effects were scrutinized.
Main Results:
- Both Mn-EBDC and MPP+ induced dopaminergic neurodegeneration and subsequent microglial activation.
- Activated microglia exacerbated the neurotoxicity initiated by Mn-EBDC or MPP+.
- Proteomic analysis identified novel proteins involved in neurodegeneration-mediated microglial activation.
Conclusions:
- Neurodegeneration precedes and drives microglial activation in response to parkinsonian toxicants.
- Activated microglia amplify neurotoxicity, suggesting a critical role in Parkinson disease progression.
- Novel protein mediators of this process have been identified, offering potential therapeutic targets.
